图 1.

CIP发病前后肺部CT。A：第6周期纳武利尤单抗治疗后胸部CT（2019年6月10日）：表现为肺气肿、肺大泡和局限性淋巴管炎；B：第8周期纳武利尤单抗治疗后胸部CT（2019年10月5日）：表现为弥漫的磨玻璃样影伴网格状改变以及沿支气管分布的结节状斑片状实变影；C：第9周期纳武利尤单抗治疗后胸部CT（2019年10月28日）：表现为弥漫的磨玻璃样影伴网格状改变以及沿支气管分布的结节状斑片状实变影。

Pulmonary CT before and after the onset of CIP. A: Chest CT after treatment with Nivolumab in cycle 6 (June 10, 2019): emphysema, pulmonary bullae and localized lymphangitis; B: Chest CT after treatment with Nivolumab in cycle 8 (October 5, 2019): diffuse ground glass opacity with grid like changes and nodular patchy consolidation along the bronchus; C: Chest CT after treatment with Nivolumab in cycle 9 (October 28, 2019): diffuse ground glass opacity with grid like changes and nodular patchy consolidation along the bronchus. CIP: immune checkpoint inhibitor associated pneumonia; CT: computed tomography.